## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Chu et al.

Serial No.: 10/643,649

Confirmation No.: Unknown

Filed:

August 18, 2003

For:

**METHODS AND APPARATUS** 

FOR TREATMENT OF

ANEURYSMAL TISSUE

 $\omega$ Group Art Unit: Unknown

Examiner:

Unknown

Customer Number:

MAIL STOP DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir or Madame:

## CERTIFICATE OF MAILING 37 CFR 1.8

I hereby certify that this correspondence is being deposited on December 15, 2003 with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

12/15 **/**03

Date

## INFORMATION DISCLOSURE STATEMENT

The Applicants, and the Attorney who signs below on the basis of the information supplied by the inventor and the information in his file, submit herewith patents, publications, or other information of which they are aware, which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56.

While the information submitted in this Information Disclosure Statement may be material pursuant to 37 CFR § 1.56, it is not intended to constitute an admission that any patent, publication, or other information referred to therein is prior art for this invention unless specifically designated as such.

In accordance with 37 CFR § 1.97, this Information Disclosure Statement is not to be construed as a representation that a search has been made or that no other possibly material information as defined under 37 CFR § 1.56(a) exists.

The patents and/or publications submitted herewith are set forth on the attached Forms PTO-SB08A and SB08B.

While we believe that no fee is due, if the sum of \$180.00 is due under 37 CFR § 1.17(p) pursuant to § 1.97, the Commissioner is hereby authorized to charge this fee, and any other fee necessary to make this submission timely, to the Deposit Account No. 20-0782/PA1515 (MEDT/0018/SB).

Respectfully submitted,

Sarah J. Brashears

Registration No. 38,087

Telephone: (650) 330-2310 Facsimile: (650) 330-2314 Attorney for Applicant(s)

241731\_1

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Pape no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form

Sheet 1

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/643,649			
Filing Date	August 18, 2003			
First Named Inventor	Chu et al.			
Art Unit	Unknown			
Examiner Name	Unknown			
Attorney Docket Number	DA1515 (MEDT/0019)			

			U. S. PATEN	T DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US- 2002/0065546	05/30/2002	Machan et al.	· igaioo i ippoui
	2	US- 5,538,504	07/23/1996	SciMed Life Systems, Inc.	·····
				<del></del>	
	3	US- 5,670,161	09/23/1997	Healy et al.	
	4	<sup>US-</sup> 5,834,449	12/10/1998	The Research Foundation of State	University of
		US-		New York; Washington University	
	5	<sup>US-</sup> 6,159,239	12/12/2000	Prodesco, Inc.	
	6	<sup>US-</sup> 6,190,353	02/20/2001	TransVascular, Inc.	
	7	US- 6,302,870	10/16/2001	Precision Vascular Systems, Inc.	
	8	<sup>US-</sup> 6,344,035	02/05/2002	Surmodics, Inc.	
	9	<sup>US-</sup> 6,348,050	02/19/2002	Medtronic, Inc.	
	10	<sup>US-</sup> 6,364,903	04/02/2002	Meadox Medicals, Inc.	
	11	<sup>US-</sup> 6,368,346	04/09/2002	American Medical Systems, Inc.	
	12	<sup>US-</sup> 6,371,970	04/16/2002	Incept LLC	
	13	<sup>US-</sup> 6,376,742	04/23/2002	Zdrahala et al.	
	14	<sup>US-</sup> 6,387,121	05/14/2002	Inflow Dynamics Inc.	
	15	<sup>US-</sup> 6,451,373	09/17/2002	Advanced Cardiovascular Systems	, Inc.
	16	<sup>US-</sup> 6,506,410	01/14/2003	Kong Kook Pharmaceutical Co., Lt	d.
	17	<sup>US-</sup> 6,514,515	02/04/2003	Tepha, Inc.	
	18	<sup>US-</sup> 6,531,154	03/11/2003	Brown University Research Found	ation

	FORE	IGN PATENT DOCU	JMENTS		
Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
	Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			ד'
1	WO-02/15824-A2	02/28/2002	Kensey Nash Corporation		
 					L
 					L

Examiner Signature	Date	
Oignature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PA1515 (MEDT/0018)

Under the Paper no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Kn wn Substitute for form 1449 ROOF **Application Number** 10/643,649 INFORMATION DISCLOSURE **Filing Date** August 18, 2003 STATEMENT BY APPLICANT **First Named Inventor** Chu et al. Art Unit Unknown (Use as many sheets as necessary) **Examiner Name** Unknown Attorney Docket Number Sheet 2

3

of

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS	
Initials*	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	1	"Beta-Blockers (Beta-Adrenergic Blocking Drugs)." <u>Texas Heart Institute Heart Information Center</u> . 18 March 2003 <a href="http://www.tmc.edu/thi/betameds.html">http://www.tmc.edu/thi/betameds.html</a> .	
	2	"Beta Blockers." <u>Cardiac Consultants.</u> 18 March 2003 <a href="http://www.cardiacconsultants.com/beta.htm">http://www.cardiacconsultants.com/beta.htm</a> .	
	3	"Beta Blockers (Beta-Adrenergic Bockers, Beta 1 Blockers, Beta 2 Blockers, B-Blockers)." <u>HeartCenterOnline</u> . 18 March 2003 <a href="http://www.heartcenteronline.com/myheartdr/common/articles.cfm?ARTID=331">http://www.heartcenteronline.com/myheartdr/common/articles.cfm?ARTID=331</a> .	
	4	"beta-blocker." Bartleby.com. 18 March 2003 <a href="http://www.bartleby.com/65/be/beta-b.html">http://www.bartleby.com/65/be/beta-b.html</a> .	
	5	Slaiby, Jeffrey M. et al. "Expansion of aortic aneurysms is reduced by proparanolol in a hypertensive rat model." <u>Journal of Vascular Surgery</u> . 21 January 2002 <a href="http://www.harcourthealth.com/scripts/om.dll/serve?action=searchDB&amp;searchDBfor=art&amp;a&gt;.">http://www.harcourthealth.com/scripts/om.dll/serve?action=searchDB&amp;searchDBfor=art&amp;a&gt;."</a>	
	6	Vine, N. et al. "Metalloproteinases in degenerative aortic disease." <u>Clinical Science</u> 1991, 81: 233-239.	
	7	Goodman, Louis Sanford and Albert Gilman. The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2001.	
	8	Jackson, Edwin K. "Renin and Angiotensin." 809-835.	
	9	Liao, Shixiong et al. "Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors." <u>Journal of Vascular Surgery</u> . May 2001, 33, No. 5: 1057-1064.	
	10	Chaikof, Elliot L. et al. "Biomaterials and Scaffolds in Reparative Medicine." <u>Annals New York Academy of Sciences</u> 2002, 961: 96-105.	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed applicant form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwo ersons are required to respond to a collection of information unless it contains a valid OMB control number, Substitute for form 1449/A Complete if Known **Application Number** 10/643,649 INFORMATION DISCLOSURE Filing Date August 18, 2003 STATEMENT BY APPLICANT **First Named Inventor** Chu et al. Art Unit Unknown (Use as many sheets as necessary) **Examiner Name** Unknown Attorney Docket Number Sheet 13 3 PA1515 (MEDT/0018)

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	11	Griffith, Linda G. "Emerging Design Principles in Biomaterials and Scaffolds or Tissue Engineering." Annals New York Academy of Sciences 2002, 961: 83-95.		
	12	Ochoa, Erin R. et al. "An Overview of the Pathology and Approaches to Tissue Engineering."  Annals New York Academy of Sciences 2002, 979: 10-26.		
	_			
Examiner	1	Date		

Signature Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.